L. Tozzi

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life

G. de Rosa, A. Faggiano, A. Colao, 2015, Oncotarget.

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

A. Colao, A. Faggiano, R. Modica, 2019, Endocrine.

Postchemotherapy residual masses in germ cell tumor patients: our experience.

E. Maiello, M. Bisceglia, F. Morelli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer.

A. Tartarone, G. Lelli, L. Tozzi, 1999, Journal of chemotherapy.

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

M. Papotti, A. Priola, N. Fazio, 2014, BMC Cancer.

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Erin L. Schenk, T. Burns, D. Camidge, 2020 .

Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score

G. de Rosa, A. Faggiano, A. Colao, 2015, Alimentary pharmacology & therapeutics.